Technical Analysis for RLMD - Relmada Therapeutics, Inc.

Grade Last Price % Change Price Change
B 37.07 6.04% 2.11
RLMD closed up 6.04 percent on Thursday, April 22, 2021, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical RLMD trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Up 3 Days in a Row Strength 0.00%
20 DMA Resistance Bearish 6.04%
50 DMA Resistance Bearish 6.04%
Bullish Engulfing Bullish 6.92%
Doji - Bullish? Reversal 7.48%
Down 3 Days in a Row Weakness 7.48%
Older End-of-Day Signals for RLMD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1 ATR about 19 hours ago
Down 2 % about 21 hours ago
Up 5% about 21 hours ago
Up 3% about 22 hours ago
Rose Above 20 DMA about 23 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Diseases Neuroscience Symptoms Neurological Disorders Urological Disorders Neurochemistry Glutamate Drug Rehabilitation Nmda Receptor Antagonists

Is RLMD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 54.0
52 Week Low 28.4
Average Volume 68,931
200-Day Moving Average 35.89
50-Day Moving Average 35.29
20-Day Moving Average 35.50
10-Day Moving Average 35.61
Average True Range 1.95
ADX 12.3
+DI 22.49
-DI 17.81
Chandelier Exit (Long, 3 ATRs ) 33.20
Chandelier Exit (Short, 3 ATRs ) 36.95
Upper Bollinger Band 38.48
Lower Bollinger Band 32.51
Percent B (%b) 0.76
BandWidth 16.82
MACD Line 0.15
MACD Signal Line 0.18
MACD Histogram -0.0238
Fundamentals Value
Market Cap 602.07 Million
Num Shares 16.2 Million
EPS -1.68
Price-to-Earnings (P/E) Ratio -22.08
Price-to-Sales 0.00
Price-to-Book 4.64
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 41.80
Resistance 3 (R3) 41.30 39.22 41.01
Resistance 2 (R2) 39.22 38.02 39.47 40.74
Resistance 1 (R1) 38.15 37.28 38.69 38.65 40.48
Pivot Point 36.07 36.07 36.34 36.32 36.07
Support 1 (S1) 35.00 34.87 35.54 35.50 33.66
Support 2 (S2) 32.92 34.13 33.17 33.40
Support 3 (S3) 31.85 32.92 33.13
Support 4 (S4) 32.35